Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Outcome of discontinuing bevacizumab prior to malignant glioma progression.

× No keyword cloud information.

3 in total

1. Bevacizumab antiangiogenic therapy for glioblastoma.

Authors: Larry Junck
Journal: Neurology Date: 2011-02-01 Impact factor: 9.910

Review 2. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Authors: Joost J C Verhoeff; Olaf van Tellingen; An Claes; Lukas J A Stalpers; Myra E van Linde; Dirk J Richel; William P J Leenders; Wouter R van Furth
Journal: BMC Cancer Date: 2009-12-16 Impact factor: 4.430

3. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors: A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal: Neurology Date: 2008-03-04 Impact factor: 9.910

3 in total

5 in total

1. Bevacizumab rechallenge in glioblastoma patients with initial response to bevacizumab who later progress off therapy.

Authors: Carmen Balana; Anna Estival; Estela Pineda
Journal: J Neurooncol Date: 2018-05-18 Impact factor: 4.130

Review 2. Bevacizumab and other novel therapies for recurrent oligodendroglial tumors.

Authors: Sean A Grimm; Marc C Chamberlain
Journal: CNS Oncol Date: 2015-10-28

3. Prolonged survival after bevacizumab rechallenge in glioblastoma patients with previous response to bevacizumab^†.

Authors: Carmen Balaña; Anna Estival; Estela Pineda; Juan Sepúlveda; Carles Mesía; Sonia Del Barco; Miguel Gil-Gil; Max Hardy; Alberto Indacoechea; Andrés Felipe Cardona
Journal: Neurooncol Pract Date: 2016-12-09

4. Continuing or ceasing bevacizumab beyond progression in recurrent glioblastoma: an exploratory randomized phase II trial.

Authors: Elizabeth J Hovey; Kathryn M Field; Mark A Rosenthal; Elizabeth H Barnes; Lawrence Cher; Anna K Nowak; Helen Wheeler; Kate Sawkins; Ann Livingstone; Pramit Phal; Christine Goh; John Simes
Journal: Neurooncol Pract Date: 2017-05-25

5. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.

Authors: Yongjun Cha; Yu Jung Kim; Se-Hoon Lee; Tae-Min Kim; Seung Hong Choi; Dong-Wan Kim; Chul-Kee Park; Il Han Kim; Jee Hyun Kim; Eunhee Kim; Byungse Choi; Chae-Yong Kim; In Ah Kim; Dae Seog Heo
Journal: Cancer Res Treat Date: 2016-05-18 Impact factor: 4.679